A chimeric cytokine receptor, which comprises a truncated il2rbeta and il2rgamma
Patent Information
- Application Number
- HK62026123720
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-20
- Filing Date
- 2026-05-20
- Publication Date
- 2026-09-11
Smart Images

Figure 00000076_0000 
Figure 00000077_0000 
Figure 00000077_0001
Abstract
Description
Abstract This invention provides a chimeric cytokine receptor comprising an intracellular domain of a cytokine receptor, the intracellular domain comprising a first strand and a second strand, wherein both the first and second strands of the intracellular domain of the cytokine receptor are truncated. The invention also provides cells comprising such a chimeric cytokine receptor, optionally in combination with a chimeric antigen receptor (CAR), and its use in the treatment of diseases such as autoimmune diseases and cancer.
Claims
CLAIMS1. A chimeric cytokine receptor, which comprises two polypeptides:(i) a first polypeptide which comprises:(a) a first dimerization domain; and(b) a truncated IL2 receptor p-chain endodomain which comprises the sequence shown as SEQ ID No. 2 with a C-terminal truncation of between about 10 and about 70 amino acids; and(ii) a second polypeptide which comprises:(a) a second dimerization domain which dimerises with the first dimerization domain; and(b) a truncated common y-chain endodomain which comprises the sequence shown as SEQ ID No. 1 with a C-terminal truncation of between about 10 and about 30 amino acids.
2. A chimeric cytokine receptor according to claim 1, wherein the truncated IL2 receptor p-chain endodomain of the first polypeptide has the sequence shown as SEQ ID No. 58.
3. A chimeric cytokine receptor according to claim 1 or 2, wherein the truncated common y-chain endodomain of the second polypeptide has the sequence shown as SEQ ID No. 62.
4. A chimeric cytokine receptor according to any preceding claim, wherein the first and second dimerization domains dimerise spontaneously.
5. A chimeric cytokine receptor according to any preceding claim, where the first and second dimerization domains dimerise in the presence of a chemical inducer of dimerization (CID) or the presence of a ligand.
6. A chimeric cytokine receptor according to claim 4 wherein: the first dimerization domain comprises a heavy chain constant domain (CH) and the second dimerization domain comprises a light chain constant domain (CL); or the first dimerization domain comprises a light chain constant domain (CL) and the second dimerization domain comprises a heavy chain constant domain (CH).
7. A chimeric cytokine receptor according to claim 5 which comprises two polypeptides:(i) a first polypeptide which comprises:(a) a first antigen-binding domain which binds a first epitope of the ligand; and(b) a truncated IL2 receptor p-chain endodomain which comprises the sequence shown as SEQ ID No. 2 with a C-terminal truncation of between about 10 and about 70 amino acids; and(ii) a second polypeptide which comprises:(a) a second antigen-binding domain which binds a second epitope of the ligand; and(b) a truncated common y-chain endodomain which comprises the sequence shown as SEQ ID No. 1 with a C-terminal truncation of between about 10 and about 30 amino acids.
8. A chimeric cytokine receptor according to claim 7, wherein each of the first and second antigen-binding domains are single-chain variable fragments (scFvs).
9. A chimeric cytokine receptor according to claim 7, wherein each of the first and second antigen-binding domains are single domain binders (dAbs).
10. A chimeric cytokine receptor according to claim 5, which comprises two polypeptides:(i) a first polypeptide which comprises:(a) a heavy chain variable domain (VH)(b) a truncated IL2 receptor p-chain endodomain which comprises the sequence shown as SEQ ID No. 2 with a C-terminal truncation of between about 10 and about 70 amino acids; and(ii) a second polypeptide which comprises:(a) a light chain variable domain (VL)(b) a truncated common y-chain endodomain which comprises the sequence shown as SEQ ID No. 1 with a C-terminal truncation of between about 10 and about 30 amino acids wherein the VH and VL associate forming a ligand-binding site.
11. A chimeric cytokine receptor according to any of claims 7 to 10, wherein the ligand is a tumour secreted factor selected from: prostate-specific antigen (PSA),carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF) and CA125.
12. A chimeric cytokine receptor according to any of claims 7 to 10, wherein the ligand is a chemokine selected from: CXCL12, CCL2, CCL4, CCL5 and CCL22.
13. A cell which comprises a chimeric cytokine receptor according to any preceding claim.
14. A cell according to claim 13, which also comprises a chimeric antigen receptor.
15. A nucleic acid construct encoding a chimeric cytokine receptor according to any of claims 1 to 13 which comprises a first nucleic acid sequence encoding the first polypeptide; and a second nucleic acid sequence encoding the second polypeptide.
16. A nucleic acid construct according to claim 15 which also encodes a chimeric antigen receptor (CAR).
17. A nucleic acid construct according to claim 15 or 16 which comprises an MND promoter.
18. A vector comprising a nucleic acid construct according to any of claims 15 to 17.
19. A vector according to claim 18 which is a lentiviral vector.
20. A kit which comprises: i) a vector comprising a nucleic acid sequence encoding a first polypeptide as defined in any of claims 1 to 13; and ii) a vector comprising a nucleic acid sequence encoding a second polypeptide as defined in any of claims 1 to 13.
21. A kit according to claim 20 which also comprises a vector comprising a nucleic acid sequence encoding a chimeric antigen receptor.
22. A method for making a cell according to claim 13 or 14, which comprises the step of introducing: a nucleic acid construct according to any of claims 15 to 17; a vector according to claim 18 or 19; or a kit of vectors according to claim 20 or 21, into a cell ex vivo.
23. A method according to claim 22, wherein the cell is from a sample isolated from a subject.
24. A pharmaceutical composition comprising a plurality of cells according to claim 13 or 14.
25. A method for treating a disease, which comprises the step of administering a pharmaceutical composition according to claim 24 to a subject.
26. A method according to claim 25, which comprises the following steps:(i) isolation of a cell-containing sample from a subject;(ii) transduction or transfection of the cells with: a nucleic acid construct according to any of claims 15 to 17; a vector according to claim 18 or 19; or a kit of vectors according to claim 20 or 21; and(iii) administering the cells from (ii) to the subject.
27. A method according to claim 26, wherein the sample is a T-cell containing sample.
28. A method according to claim 26 or 27, wherein the disease is a cancer, an infectious disease or an autoimmune disease.
29. A pharmaceutical composition according to claim 24 for use in treating a disease.
30. The use of a cell according to claim 13 or 14 in the manufacture of a medicament for treating a disease.
